Pediatric TB Presentation
Transcript of Pediatric TB Presentation
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 1/63
0
Pediatric Tuberculosis
Ann M. Loeffler, MDPediatric TB Consultant
Francis J. Curry National Tuberculosis Center
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 2/63
1
IntroductionBasic situations in which children areevaluatedDiagnosis and treatment of latent TB
infection (LTBI)Tuberculosis (TB) treatment strategies
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 3/63
2
Reasons for complacencePediatric TB is uncommon in the U.S.In 2004, 961 pediatric TB cases in the U.S.
Young children with TB are usually not
contagiousAdults with TB are relatively easy to identify
More symptomatic and can produce sputum
Children with TB are difficult to diagnose
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 4/63
3
Reasons to learn about pediatric TBWorldwide, 500,000 children die annuallyfrom TBChildren represent up to 30% of TB cases
globally, compared to 7% in U.S.Children age 0-4 are more likely to develop TBonce infected and are more vulnerable todisseminated TBChildren serve as indicators of contagious
adolescents or adults with TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 5/63
4
Three basic situations1. General pediatric care for healthy children
Screen for TB risk factors
2. Child contacts to adults with potentially
contagious TBEvaluation and intervention required
3. Children with signs or symptoms of TB orradiographic changes
High index of suspicion required
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 6/63
5
Quiz question
Which situation yields the most cases of TBin children?
Screening of healthy, asymptomatic childrenScreening of children exposed to contagiousadults with TB
Evaluation of children with symptomsconcerning for TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 7/63
6
How are most cases found?From various studies published in the U.S.:
26-80% of children with TB identified duringcontact investigations3-25% of cases identified by routine screening17-44% of cases presented because of
symptomsIn developing countries, no screening of
asymptomatic children.
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 8/63
7
Routine pediatric care:No more universal testing
It is not cost-effective to routinely skin testhealthy children without risk for TB infection or
disease!Preferred strategy: “targeted testing”
Test only children more likely to be exposed to TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 9/63
8
Advantages of targeted testing
Up to 85% of positive results will be FALSEpositives in areas of low TB prevalenceMore expense, anxiety, and unnecessary
evaluations and treatmentTST is not free, not without discomfort, and notso easy to place and interpret
Families often do not return for TST reading
TST = tuberculin skin test
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 10/63
9
Statistics about TB risk inU.S. children30% of children with TB are born outside U.S.50% are Hispanic
10% are Asian26-80% of pediatric cases are identified during
evaluation of contacts of adults with TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 11/63
1 0
Questions validated to predict risk
Was your child born in Latin America, Asia,Eastern Europe, or Africa?Since last TST, has child traveled outsidethe U.S.?Since last TST, has child been exposed toanyone with TB or with a (+) TST?
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 12/63
1 1
Questions to predict risk – local epidemiology
Since last TST, has child consumedunpasteurized dairy products from Mexico?
Since last TST, has child been around peoplewho have been incarcerated, homeless or inshelters, or people who have HIV, or use illegal
drugs?Since last TST, has child lived with new personwho was born or traveled outside U.S.?
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 13/63
1 2
Targeted TB skin testing
Don’t skin test someone you won’t treat if TST ispositive
If child has no TB exposure risks, don’t skin test!“A decision to test is a decision to treat.”
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 14/63
1 3
TST basicsStore PPD in the bottle, clearly labeled inrefrigerator; discard open bottles after 1 monthProviders who administer TST should be trainedand evaluated on TST techniqueInject 0.1 ml of PPD material intradermally into
volar aspect of forearmCorrect placement yields pale, distinct wheal,raised for several minutes
PPD = purified protein derivative
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 15/63
1 4
Reading TST resultsA trained professional should read TST results48 to 72 hours after placementA positive test has distinct induration, not just
erythema:Bend arm at elbow; look with indirect lightFeel gently with your non-dominant hand or run penacross the induration
Measure and record result in millimeters of indurationperpendicular to long axis of arm
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 16/63
1 5
TST interpretation>5 mm is (+) only if child is:
immunocompromiseda contact to a known or suspected case of TBhas clinical or radiographic evidence of TB or old TB
>10 mm is (+) for child with intermediate risk:age <4 years
medical conditions predisposing them to TB orincreased risk of TB exposure
>15 mm is (+) if child has no risk (should not be
skin tested!)
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 17/63
1 6
What about BCG?BCG vaccine is routinely given to newborns/infants inmost areas of the worldIgnore history of BCG when placing or interpreting TSTIncreased risk of positive TST results being caused by
BCGBCG received as an older infant or child (>1 month of age)Multiple BCG dosesBCG in recent past
Treat LTBI or TB based on breakpoints from last slide
BCG = bacille Calmette-Guérin vaccineLTBI = latent TB infection
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 18/63
1 7
If TST is negativeDocument results as millimeters of indurationin the chart and vaccine recordAdvise family to return to clinic if induration
increases in next few daysA (+) TST can be read up to 7 days after placement
Repeat questionnaire procedure at next well-child visitRepeat TST only if child has new risk factor
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 19/63
1 8
TB or LTBI?TB: child has metabolically active M.tuberculosis bacteria in some part of the body
Many children are asymptomatic at time of TBdiagnosis in U.S.
LTBI: organism is dormant; physical exam andradiograph are normalTo decide, perform focused history, physical
exam, and chest radiograph
TB = tuberculosis disease LTBI = latent TB infection
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 20/63
1 9
Focused Physical ExamTemperature and growth parametersAlertness and meningeal signsPeripheral lymph nodesAbdomenPalpate back and extremities
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 21/63
2 0
Lung findingsLung findings are relatively modest, even withabnormal chest radiographInfants and adolescents most likely to have
rales, decreased breath sounds, and increasedwork of breathing
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 22/63
2 1
Chest radiographTwo-view chest radiograph helps identifycommon abnormality: IntrathoraciclymphadenopathyMention symptoms and possibility of TB onradiology order formSame-day interpretation by
radiologist experienced withpediatric TB is idealWait until TB is ruled out beforestarting treatment
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 23/63
2 2
LTBI (latent TB infection)Normal chest radiograph and physical exam,(+) TST = diagnosis of LTBIWhy treat all children who have LTBI?
LTBI treatment is less toxic in children than in adultsYoung children are more likely to develop TB onceinfected than are adultsYoung children were infected recently, increasingrisk of progression to TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 24/63
2 3
Summary:Screening well childrenNo more universal TB skin testingTargeted testing: Review TB exposure andpopulation risk factors; TST only for childrenwith new exposure risks since last TSTIf (+) TST, conduct focused history and physical
exam to discern TB from LTBI
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 25/63
2 4
Child contact to a TB caseContact investigation: Evaluation of contacts toa contagious TB caseYoung children are high priority for evaluation
More likely to develop TBMay develop TB within weeks of infectionContacts < age 5: immediate chest
radiographs, history, and physical examDo not wait for (+) TST result before performingevaluation on young child,immunocompromised or symptomatic individual
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 26/63
2 5
Treatment of contactsIf (+) TST, begin 9-month course of INH for LTBI
If (-) TST, consider INH treatment as “windowprophylaxis”Repeat TST after 8-10 weeks of no further exposureto contagious caseIf TST still (-), child is immunocompetent, and nonew TB symptoms, stop INHIf exposure to contagious case has continued, or if
another adult in proximity has TB, repeat evaluationand/or extend treatmentIf (+) TST upon repeat testing, complete 9 months ofINH
INH = isoniazid
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 27/63
2 6
Child contacts > 4 yrTST and symptom reviewIf (-) TST and no symptoms, chestradiograph not imperative
Individualize use of window prophylaxis; local healthdepartment can advise youRepeat TST 8-10 weeks after contact is broken or
source case is deemed non-contagiousIf (+) TST, obtain chest radiograph if not performedinitially
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 28/63
2 7
Summary:Child contactPrompt TST and symptom reviewfor all individuals with significant exposure to contagiousTB case
Children under 5Chest radiograph even before TST is readIf no TB, start window prophylaxis, independent of TST result
8-10 weeks after exposure is ended, repeat TST. If (-)TST, stop window prophylaxis (assumingimmunocompetence)
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 29/63
2 8
Symptoms and abnormalradiographs
Difficult to distinguish community-acquiredpneumonia or asthma from TB onradiographic findingsSymptoms often subtle or even absentDifficult to confirm microbiologically
Children cannot produce sputa easilySputa from young children usually
smear (-)
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 30/63
2 9
Circumstances that increaseTB suspicion
Exposure to person with TBSeveral people in child’s environment with (+)TSTsRadiographic changes common in pediatric TB,including intrathoracic adenopathy and calcified
granulomataA relative paucity or chronicity of symptoms incomparison to radiographic changes
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 31/63
3 0
TST results are not definitiveA positive TST does not confirm thediagnosis of TBA negative TST does not exclude TB
TST results are merely one factor in theequation
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 32/63
3 1
Algorithm forDiagnosis
Positive TB skin test
Clinically and radiographically
Treat for LTBI
Other diagnosisconfirmed; courseinconsistent with TB
Note: Cultures only help if they are positive.See the next few slides for more algorithm details.
Reassess weekly
TB still possible?
Collect cultures & start4-drug TB therapy
Consider culturecollection(no INH!)
Treat other
diagnosis
Patient very stable?
More consistent with otherdiagnosis
Consistentwith TB
Abnormal
YES
NO
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 33/63
3 2
Findings more consistent with another
diagnosis…
Consider culturecollection(no INH!)
Treat otherdiagnosis
Patient very stable?
More consistent with otherdiagnosis
abnormal
YES
Chest radiograph
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 34/63
3 3
If radiograph normalizes without TBtreatment…
Consider culturecollection(no INH!)
Treat otherdiagnosis
Treat for LTBI
Other diagnosis
confirmed; courseinconsistent with TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 35/63
3 4
If findings do not normalize…
Consider culturecollection(no INH!)
Treat otherdiagnosis
Reassess weekly
TB still possible?
Collect cultures & start4-drug TB therapy
Consistentwith TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 36/63
3 5
OK to overtreat in uncertainsituations
If patient is not stable: Submit specimens forcultures and start TB therapy; sometimesdiagnosis becomes clear over timeSometimes diagnosis doesn’t become certain;complete treatment for TB
Weigh all likely diagnoses, consider risks andbenefits, and make best judgment afterdiscussion with family and expert resources
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 37/63
3 6
When TB is most likely diagnosis…
Consider culturecollection(no INH!)
Treat otherdiagnosis
Positive TB skin test
Clinically and radiographically
Collect cultures & start4-drug TB therapy
Consistentwith TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 38/63
3 7
ScrofulaScrofula: peripheral mycobacterial lymph
nodesTypically enlarge over several weeks; nottender unless they enlarge quicklyOverlying skin discolors, first pink, thendusky or purplish
Different from pyogenic lymph nodesChildren with TB scrofula
often have (+) TST
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 39/63
3 8
Scrofula in briefTB scrofula
Tends to occur in children over 5Associated with TB exposure or risk factors: Travel toendemic areas and consumption of unpasteurized dairyproducts ( M. bovis )
Most often in cervical chains (could be anywhere)Associated with larger TST induration
Non-tuberculous or atypical mycobacterial scrofula
More likely in children < 5More frequently in submandibular and submental chains.Cat Scratch Disease
More common in axilla and groinExposure to kittens and history of scratches common
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 40/63
3 9
Clinical suspicion, negative TST
A negative TST never rules out TB20% of culture-proven pediatric TB cases areTST (-) when initially evaluated
Pursue diagnosis and treatment of TB:Known source caseRadiographic abnormalities most consistent with TB
Clinical findings are subtle or more modest thanradiographic findingsIntrathoracic lymphadenopathy
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 41/63
4 0
QuantiFERON ®
-TB Gold testNew option for clarifying dx of TB infectionAliquots of whole blood are exposed to TB-specific proteins and controls
Plasma is tested for levels of gamma-interferonTest is (+) if the lymphocytes have recognizedTB proteins and produced gamma-interferon
well above the level in control tubeQFT-G can distinguish true TB infections fromthose caused by NTM or BCG exposure
QFT-G = QuantiFERON ®
-TB Gold NTM = nontuberculous mycobacteria
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 42/63
4 1
Limitations of QFT-GCDC advises caution when interpreting QFT-G inchildren and immunocompromisedStudy results regarding children are mixed
QFT-G most useful in identifying true infection inhealthy asymptomatic BCG-vaccinated individualsIn pediatric TB suspects and high-risk contacts < 5,
use QFT-G in confusing situations as one morepiece of informationNeither negative TST nor QFT-G ever rules out TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 43/63
4 2
QuantiFERON ®
-Gold In TubeNext generation QuantiFERON ®
Blood is collected into tubes coatedwith stimulating proteinsNo need to transport blood within 12 hours to labOne pediatric study:
Good correlation with TST
Both QFT-G In Tube and TST were (-) in severalchildren with TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 44/63
4 3
T-SPOT. ®
TB
Quite promising for childrenGamma-interferon release assay
Requires separation of peripheral bloodmononuclear cells from whole bloodTechnically more challenging than QFT-Gtests
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 45/63
4 4
Culture collectionSputum: Older children can collect sputumby induction or in showerGastric aspirate
Highest yield specimen for infants~ 50% yield in children with TB
Other specimens: Cerebrospinal fluid, lymphnode tissue, blood, urine, bone biopsy,synovial fluidSubmit large volume specimens in sterile
container without formalin
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 46/63
4 5
Summary: DiagnosisNot everyone with (+) TST has TB
Not everyone with TB has (+) TSTConsider TB exposure, TST results,signs/symptoms, and radiographic featuresTest for other likely diagnosesConsider a therapeutic trial of bronchodilator
therapy or single course of antibioticsUtilize dedicated TB clinic or expert pediatric TBconsultants
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 47/63
4 6
Reporting casesDetermine local requirements for reportingpatients to local health department (LHD)Report suspected cases of TB to LHD within 1
working dayNo universal reporting requirement for LTBI
LTBI = latent TB infection
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 48/63
4 7
Treatment of LTBI
All children with LTBI should be treated270 doses of isoniazid (INH)
Minimum 9 monthsGoal is to finish 270 doses within 12months
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 49/63
4 8
Tips for completing therapyGive a big pep talk at beginning of therapyExplain:
Benefit of treatment
Consequences if child were to activate the TBUse INH tablets, not liquid, to avoid abdominalpain and diarrhea
Minimize GI side effects by giving drug withsnack and/or at bedtime
Provide calendar and stickers
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 50/63
4 9
Monthly visits during therapy
Ensure adherenceMonitor for toxicityArrange for quick nurse visits
Only dispense bottles of 30 INH doses; no refillsWhen child has finished 9 bottles, course is doneProvide toy or incentive to keep child engagedOr offer incentive at end of therapy (movie tickets,fast food voucher, toy, etc.)
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 51/63
5 0
Liver toxicity
Liver function testing (LFT) is no longer standard
Most children tolerate therapy wellLFT’s only for children with:
Underlying liver diseaseTaking other hepatotoxic medsSymptoms of hepatotoxicity
Watch for anorexia, malaise, abdominal painMake sure family stops treatment and returns forevaluation if symptoms develop
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 52/63
5 1
B6 tableAGE OF CHILD PYRIDOXINE DOSE
Infant 6.25 mg ¼ of 25 mg tablet
Toddler 12.5 mg ½ of 25 mg tablet
School-aged 25 mg 25 mg tablet
Vitamin B6 (pyridoxine) dosing in children
Tablet can be crushed or fragmented into liquid orsoft vehicles.
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 53/63
5 2
Summary: LTBI treatmentMost difficult thing: getting child to take all 270dosesLet family know what to expectTeach good tricks for dosingProvide incentivesEnsure families understand symptoms of
drug toxicityMonthly visits are important; keep them quick
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 54/63
5 3
Treatment of TBSend child to TB clinic with pediatric expertise
Confer with local health department andpediatric TB consultantFour-drug empiric therapy using directly
observed therapy (DOT)DOT: Non-family member observes patient takingmedicationDOT can increase completion rates to 90% rangeCan take place at home, work, school, clinic, orstreet corner
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 55/63
5 4
Four-drug treatment tableDRUG DAILY dose
in mg/kg/dose(maximum dose)
TWICE WEEKLYdose in mg/kg/dose(maximum dose)
Isoniazid 10-15 (300 mg)* 20-30 (900 mg)
Rifampin 10-20 (600 mg)* 10-20 (600 mg)
Pyrazinamide 20-40 (2 grams) 50 (2 grams)
Ethambutol # 15-25 (2.5 grams) 50 (2.5 grams)
American Academy of Pediatrics
* When using both INH and Rifampin DAILY, dose INH at 10/mg/kg/dose andRifampin no more than 15 mg/kg
# Consider risk and benefit of Ethambutol in children whose visual acuity cannot bemonitored.
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 56/63
5 5
Course of treatment
Isoniazid
Rifampin
Ethambutol
0 1 2 3 4 5 6months
Initial Phase Continuation Phase
Ethambutol can be stopped if the patient or source case isolate is INH/RIF susceptible.
Pyrazinamide
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 57/63
5 6
After 2 months of therapyAfter two months, regimen can be changed to INH
and RIF by DOT 2 to 3 times weekly if:Patient is doing well (gaining weight and not
worsening clinically or radiographically)Patient is taking and retaining each DOT dose,and appears to be absorbing the drugs
And there is no concern for drug resistance
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 58/63
5 7
Assess the course of treatmentAt two months:
Repeat chest radiograph and assessthe situation.If adherence and response are goodand no particular concern for resistance,treat with INH and RIF for remainder of course
Total duration of therapy is six months, measured by
number of doses observedPatients receiving a typical regimen receive 40 daily dosesand 36 twice-weekly doses
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 59/63
5 8
Challenges of treating childrenMicrobiologic confirmation is less common
Monitoring success by serial sputum isnearly impossibleMonitoring for toxicity is more difficultChildren tolerate regimens better than adultsINH liquid is poorly tolerated
Need to open capsules, crushtablets, hide drug into soft foodsor liquids
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 60/63
5 9
Dosing tipsAnticipate trial-and-error period for 1-2 weeks
Don’t alienate child while figuring out agood systemPossible vehicles: Maple syrup, chili, nutella,spinach baby food, chocolate whipped creamLayer vehicle and drug on a spoonTeach child to take contents of spoonwithout chewingBe prepared to try new tricks or incentives
Never let child think the dose is optional
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 61/63
6 0
Circumstances for prolongedtherapyIf disease is extensive or slow to respondIf patient has TB meningitis or osteomyelitis(treated for 12 mo)If TB isolate is drug-resistant
Includes treatment of M. bovis (inherently resistant
to PZA and often sluggishly responsive to therapy)If patient has been poorly adherent
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 62/63
6 1
ConclusionPediatric TB is relatively uncommon in U.S. and
sometimes missedScreen healthy children with risk factorquestionnaires and reserve TST for those at risk
of exposureEvaluate children exposed to active cases of TBpromptly and thoroughly; they are at highest riskof infection and diseaseNot all children with TB have (+) TST and not allchildren with (+) TSTs and radiographicabnormalities have TB
8/14/2019 Pediatric TB Presentation
http://slidepdf.com/reader/full/pediatric-tb-presentation 63/63
6 2
Next stepsProceed to the post-test
Peruse course resource materialsShare the resources with friends and colleagues
Call a pediatric TB expert for assistance
Thank you for your careof the children.